Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Respiratory Journal

• Publication date

  2011-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.00010111PMID 21778168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A prospective, randomized trial comparing the Vienna nomogram to an eight‐core prostate biopsy protocol

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011influential reference
• Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-Enriched Sequencing in Chinese Patients with Advanced Non-Small Cell Lung Cancer

  2011cited by this paper
• WHO histological classification of tumours of the vulva

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

  2010cited by this paper
• Frequency of and variables associated with the EGFR mutation and its subtypes

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

  2010cited by this paper
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• F1000 highlights

  2009influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients

  2009cited by this paper
• Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: The Memorial Sloan-Kettering experience

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008influential reference
• Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

  2008cited by this paper
• How to build and interpret a nomogram for cancer prognosis.

  2008cited by this paper
• Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

  2008influential reference
• Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas

  2007cited by this paper
• The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer

  2007cited by this paper
• Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

  2006cited by this paper
• Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

  2006cited by this paper
• Worldwide trends in lung cancer pathology

  2006cited by this paper
• EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib

  2006cited by this paper
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

  2006cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma

  2005cited by this paper
• [World Health Organization classification of tumours, pathology and genetics of tumours of the lung].

  2005cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Nomograms Inserted into NCCN Prostate Cancer Guidelines

  2003cited by this paper
• A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

  1998cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells

  2025cites this paper
• Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients

  2025cites this paper
• CT-based radiomics and deep learning to predict EGFR mutation status in lung adenocarcinoma

  2025cites this paper
• EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer

  2025cites this paper
• Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

  2024cites this paper
• METnet: A novel deep learning model predicting MET dysregulation in non-small-cell lung cancer on computed tomography images

  2024cites this paper
• Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels

  2024cites this paper
• Improved Prediction of Epidermal Growth Factor Receptor Status by Combined Radiomics of Primary Nonsmall-Cell Lung Cancer and Distant Metastasis

  2024cites this paper
• Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer

  2024cites this paper
• Non-invasive, fast, and high-performance EGFR gene mutation prediction method based on deep transfer learning and model stacking for patients with Non-Small Cell Lung Cancer

  2024cites this paper
• Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images

  2023cites this paper
• Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer

  2023cites this paper
• Predicting EGFR gene mutation status in lung adenocarcinoma based on multifeature fusion

  2023cites this paper
• Detection of the gene mutation of epidermal growth factor receptor in lung adenocarcinoma by radiomic features from a small amount of PET data

  2023cites this paper
• Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC

  2022cites this paper
• Deep learning analysis to predict EGFR mutation status in lung adenocarcinoma manifesting as pure ground-glass opacity nodules on CT

  2022cites this paper
• Predicting Tumor Mutation Burden and EGFR Mutation Using Clinical and Radiomic Features in Patients with Malignant Pulmonary Nodules

  2022cites this paper
• Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.

  2022cites this paper
• Radiomics for Detection of the EGFR Mutation in Liver Metastatic NSCLC.

  2022cites this paper
• Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma

  2022cites this paper
• Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study.

  2022cites this paper
• Prognostic implications of cellular senescence in resected non-small cell lung cancer

  2021cites this paper
• Multiparametric MRI‐Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma

  2021cites this paper
• Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma

  2021cites this paper
• A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)

  2021cites this paper
• Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

  2021influential citation
• CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study

  2021cites this paper
• The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status

  2021cites this paper
• Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line

  2021cites this paper
• Relationship between epidermal growth factor receptor mutations and CT features in patients with lung adenocarcinoma.

  2021cites this paper
• Piloting a Deep Learning Model for Predicting Nuclear BAP1 Immunohistochemical Expression of Uveal Melanoma from Hematoxylin-and-Eosin Sections

  2020cites this paper
• Generation of Osimertinib-Resistant Cells from EGFR L858R/T790M Mutant NSCLC Cell Line.

  2020cites this paper
• The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma

  2020cites this paper
• Mut-Detecter: An EGFR activating mutation type classification method with a deep convolutional neural network

  2020cites this paper
• Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma

  2020cites this paper
• Empirical treatment with EGF-R tyrosine kinase inhibitor for neoplastic ARDS.

  2020cites this paper
• Multi-Type Interdependent Feature Analysis Based on Hybrid Neural Networks for Computer-Aided Diagnosis of Epidermal Growth Factor Receptor Mutations

  2020cites this paper
• Catalog of Lung Cancer Gene Mutations Among Chinese Patients

  2020cites this paper
• Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report

  2020cites this paper
• Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand

  2020cites this paper
• Profils moléculaires des cancers bronchiques non à petites cellules à la Réunion

  2020cites this paper
• Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

  2020cites this paper
• Survival-associated alternative splicing signatures in non-small cell lung cancer

  2020cites this paper
• Pyramid Focusing Network for mutation prediction and classification in CT images

  2020cites this paper
• EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India

  2020cites this paper
• Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning

  2019cites this paper
• Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

  2019cites this paper
• Prediction of BAP1 Expression in Uveal Melanoma Using Densely-Connected Deep Classification Networks

  2019cites this paper
• Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer

  2019cites this paper
• Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old

  2019cites this paper
• Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.

  2019cites this paper
• Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status

  2019cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma.

  2018cites this paper
• Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma

  2018cites this paper
• The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis—a retrospective study on digitalized slides

  2018cites this paper
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy

  2018cites this paper
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases

  2018cites this paper
• Development and validation of a model to predict tyrosine kinase inhibitor‐sensitive EGFR mutations of non‐small cell lung cancer based on multi‐institutional data

  2018cites this paper
• CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation

  2017cites this paper
• Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems

  2017cites this paper
• In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy

  2017cites this paper
• Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine

  2017cites this paper
• Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.

  2017cites this paper
• Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma

  2017cites this paper
• Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice

  2017cites this paper
• Worldwide Frequency of Commonly Detected EGFR Mutations.

  2017cites this paper
• Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.

  2016cites this paper
• Supplementary Table 4: Cox's multivariate regression analysis for factors affecting overall survival in patients with Stage IV disease

  2016cites this paper
• Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice

  2016cites this paper
• Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes

  2016cites this paper
• Somatic alterations in lung cancer: Do environmental factors matter?

  2016cites this paper
• Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

  2016cites this paper
• ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India

  2016cites this paper
• Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival

  2016influential citation
• Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

  2016cites this paper
• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

  2016cites this paper
• Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

  2016cites this paper
• Should the treatment of advanced lepidic adenocarcinoma be adapted to the pathological subtype?

  2015cites this paper
• Advances in target therapy in lung cancer

  2015cites this paper
• Introduction à la série thématique « Thérapies ciblées dans les cancers bronchiques »

  2015cites this paper
• Carcinomes bronchiques non à petites cellules (CBNPC) métastatiques, mutés ou réarrangés : comment déterminer la cible ?

  2015cites this paper
• ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens

  2015cites this paper
• [Introduction to the Thematic Series "Targeted therapies in lung cancers"].

  2015cites this paper
• Molecular histology of lung cancer: from targets to treatments.

  2015cites this paper
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

  2015cites this paper
• Expression and amplification of the human epidermal growth fac- tor receptor 2 in different stages of urothelial bladder carcinoma

  2014cites this paper
• Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma

  2014cites this paper
• Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

  2014cites this paper
• Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma

  2014cites this paper
• Thérapies ciblées : quel traitement pour quel patient ?

  2014cites this paper
• A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population

  2014cites this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cites this paper
• Verifying the role of surgical pathologists in the precision medicine of lung cancer.

  2013cites this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cites this paper
• Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes

  2013cites this paper